Trade Aridis Pharmaceuticals, Inc. - ARDSus CFD
Add to favourite- Summary
- Historical Data
| Spread | 0.0059 | ||||||||
|
Long position overnight fee
Long position overnight funding adjustment
Go to platform | -0.024124% | ||||||||
|
Short position overnight fee
Short position overnight funding adjustment
Go to platform | 0.001901% | ||||||||
| Overnight fee time | 22:00 (UTC) | ||||||||
| Min traded quantity | 1 | ||||||||
| Currency | USD | ||||||||
| Margin | 5.00% | ||||||||
| Stock exchange | United States of America | ||||||||
| Commission on trade | 0% |
| Prev. Close | 0.2533 |
| Open | 0.294 |
| 1-Year Change | -72.26% |
| Day's Range | 0.2635 - 0.312 |
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Close | Change | Change (%) | Open | High | Low |
|---|---|---|---|---|---|---|
| Jul 18, 2023 | 0.3090 | 0.0041 | 1.34% | 0.3049 | 0.3209 | 0.2601 |
| Jul 17, 2023 | 0.2533 | -0.0607 | -19.33% | 0.3140 | 0.3166 | 0.2491 |
| Jul 14, 2023 | 0.3153 | -0.0302 | -8.74% | 0.3455 | 0.3455 | 0.3090 |
| Jul 13, 2023 | 0.3490 | 0.0454 | 14.95% | 0.3036 | 0.3588 | 0.2790 |
| Jul 12, 2023 | 0.3289 | -0.0499 | -13.17% | 0.3788 | 0.3987 | 0.3153 |
| Jul 11, 2023 | 0.2606 | 0.0114 | 4.57% | 0.2492 | 0.2669 | 0.2490 |
| Jul 10, 2023 | 0.2617 | 0.0227 | 9.50% | 0.2390 | 0.2638 | 0.2390 |
| Jul 7, 2023 | 0.2491 | 0.0257 | 11.50% | 0.2234 | 0.2502 | 0.2234 |
| Jul 6, 2023 | 0.2263 | 0.0046 | 2.07% | 0.2217 | 0.2321 | 0.2213 |
| Jul 5, 2023 | 0.2272 | 0.0080 | 3.65% | 0.2192 | 0.2332 | 0.2192 |
| Jul 3, 2023 | 0.2148 | 0.0006 | 0.28% | 0.2142 | 0.2259 | 0.2142 |
| Jun 30, 2023 | 0.2144 | -0.0025 | -1.15% | 0.2169 | 0.2169 | 0.1993 |
| Jun 29, 2023 | 0.2129 | 0.0037 | 1.77% | 0.2092 | 0.2167 | 0.2092 |
| Jun 28, 2023 | 0.2116 | -0.0276 | -11.54% | 0.2392 | 0.2392 | 0.2092 |
| Jun 27, 2023 | 0.2413 | -0.0088 | -3.52% | 0.2501 | 0.2531 | 0.2345 |
| Jun 26, 2023 | 0.2492 | -0.0099 | -3.82% | 0.2591 | 0.2591 | 0.2491 |
| Jun 23, 2023 | 0.2597 | 0.0051 | 2.00% | 0.2546 | 0.2603 | 0.2492 |
| Jun 22, 2023 | 0.2566 | -0.0025 | -0.96% | 0.2591 | 0.2591 | 0.2541 |
| Jun 21, 2023 | 0.2565 | 0.0043 | 1.70% | 0.2522 | 0.2601 | 0.2501 |
| Jun 20, 2023 | 0.2552 | -0.0014 | -0.55% | 0.2566 | 0.2671 | 0.2516 |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 2:1
- 3:1
- 5:1
- 10:1
- 20:1
- 20
- 100
- 500
- 1000
- 10000
Aridis Pharmaceuticals, Inc. Company profile
About Aridis Pharmaceuticals Inc
Aridis Pharmaceuticals, Inc. is a late-stage biopharmaceutical company. The Company is focused on the discovery and development of targeted immunotherapy using fully human monoclonal antibodies (mAbs) to treat life-threatening infections. The Company's proprietary product pipeline is comprised of fully human mAbs targeting specific pathogens associated with life-threatening bacterial and viral infections, primarily hospital-acquired pneumonia (HAP), ventilator-associated pneumonia (VAP), cystic fibrosis and COVID-19. The Company's lead product candidate, AR-301, targets the alpha toxin produced by gram-positive bacteria Staphylococcus aureus (S. aureus), a common pathogen associated with HAP and VAP. Its clinical development activities are focused on AR-301, AR-712, and AR-501. Its development of antibody discovery and production platform technology called aPEXTM extends the capabilities of MabIgX, its differentiated antibody discovery platform.
Financial summary
BRIEF: For the nine months ended 30 September 2021, Aridis Pharmaceuticals Inc revenues decreased 45% to $548K. Net loss applicable to common stockholders increased from $16.5M to $37.5M. Revenues reflect License revenue decrease of 87% to $131K. Higher net loss reflects Research and development - Balancing val increase from $12.3M to $28.9M (expense), General and administrative - Balancing increase of 11% to $4.1M (expense).
| Industry: | Bio Therapeutic Drugs |
983 University Avenue, Bldg. B
LOS GATOS
CALIFORNIA 95032
US
News
Gold price predictions for the next five years: Third party data round up
Explore the future of gold prices and whether the yellow metal will continue its upward trend in the coming years.
15:17, 18 November 2024
Shiba Inu coin price prediction 2030: could Shiba Inu coin reach $1? Third party price target
Can Shiba Inu reinvent itself to become a worthy long-term investment?
08:36, 15 November 2024
Trump trades charge as Bitcoin hits $US80,000
Bitcoin hits $80,000 amid expectations of fiscal stimulus, lower regulatory risks, and resilient US economy.
10:48, 13 November 2024
Australian jobs data expected to point to solid labour market conditions
Australian labour market and wage data to reveal job growth resilience, shaping RBA rate cut expectations and impacting AUD amidst global economic shifts.
10:16, 13 November 2024
FOMC cuts interest rates as expected and sticks to its line on future policy
The FOMC cut interest rates by 25 basis points at its November meeting, aligning with expectations. Wall Street hit record highs following the decision, with tech stocks leading the rally. Markets are pricing in a probable December cut amid resilient economic indicators.
13:33, 8 November 2024
FOMC and BOE preview: further rate cuts expected
Both the Federal Reserve and the Bank of England are expected to cut rates further when they meet later this week.
14:14, 5 November 2024
RBA meeting preview: No change to policy expected as inflation fight continues
The Reserve Bank of Australia is expected to keep its cash rate on hold at 4.35% when it announces its policy decision at 2.30PM on the 5th of November, 2024. Despite ongoing evidence of soft demand, upside risks to inflation are likely to remain the central bank’s primary concern.
13:35, 4 November 2024People also watch
Still looking for a broker you can trust?
Join the 660,000+ traders worldwide that chose to trade with Capital.com